References
- Kumar SK, Rajkumar SV, Dispenzieri A, . Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–2520.
- Kroger N, Sayer HG, Schwerdtfeger R, . Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002;100:3919–3924.
- Badros A, Barlogie B, Morris C, . High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001;97:2574–2579.
- Badros A, Barlogie B, Siegel E, . Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002;20:1295–1303.
- Maloney DG, Molina AJ, Sahebi F, . Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003;102: 3447–3454.
- Crawley C, Lalancette M, Szydlo R, . Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the chronic leukaemia working party of the EBMT. Blood 2005;105:4532–4539.
- Kumar S. Treatment of newly diagnosed multiple myeloma in transplant-eligible patients. Curr Hematol Malig Rep 2011;6:104–112.
- Palumbo A, Attal M, Roussel M. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. Clin Cancer Res 2011;17:1253–1263.
- Palumbo A, Gay F, Bringhen S, . Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol 2008;19:1160–1165.
- San Miguel JF, Schlag R, Khuageva NK, . Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906–917.
- Dimopoulos MA, Chen C, Spencer A, . Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009;23:2147–2152.
- Fermand JP, Katsahian S, Divine M, . High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23:9227–9233.
- Blade J, Rosinol L, Sureda A, . High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005;106:3755–3759.
- Barlogie B, Kyle RA, Anderson KC, . Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006;24:929–936.
- Kroger N, Schwerdtfeger R, Kiehl M, . Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002;100: 755–760.
- Delavalade H, El-Cheikh J, Faucher C, . Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplant 2008;41:953–960.